Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Verteporfin Blocks Growth of Deadly Eye Melanoma

By BiotechDaily International staff writers
Posted on 08 Jun 2014
Image: An untreated uveal melanoma tumor (left) covers entire eye of a mouse. A tumor treated with verteporfin (right) is much smaller and much of the structure of the mouse\'s eye is visible (Photo courtesy of UCSD - University of California, San Diego).
Image: An untreated uveal melanoma tumor (left) covers entire eye of a mouse. A tumor treated with verteporfin (right) is much smaller and much of the structure of the mouse\'s eye is visible (Photo courtesy of UCSD - University of California, San Diego).
Simultaneous mutations in two G-protein encoding genes that cause the overexpression of a carcinogenic protein have been linked to the development of uveal melanoma, a deadly cancer of the colored areas of the eye.

Uveal melanoma is a rare cancer that is usually treated by surgical removal of the eye. However, uveal melanoma can spread to the liver, in which case patients typically die within two to eight months after diagnosis.

Genome studies have shown that a mutation in either the GNAQ (guanine nucleotide binding protein, q polypeptide) or GNA11 (guanine nucleotide-binding protein subunit alpha-11) genes, which encode the proteins Gq or G11, respectively, are found in about 70% of uveal melanoma tumors.

In the current study, which was published in the May 29, 2014, online edition of the journal Cancer Cell, investigators at the University of California, San Diego (USA) revealed that that these mutations cause the G-proteins to become permanently activated, which results in overexpression of the Yes-associated protein (YAP). Overexpression of YAP protein induces uncontrolled cell growth and inhibits cell death, triggering cancer development. Furthermore, treatment of uveal melanoma tumors with the YAP inhibitor drug verteporfin blocked tumor growth of cells containing Gq/G11 mutations.

“The beauty of our study is its simplicity,” said senior author Dr. Kun-Liang Guan, professor of pharmacology at the University of California, San Diego. “The genetics of this cancer are very simple and our results have clear implications for therapeutic treatments for the disease. We have a cancer that is caused by a very simple genetic mechanism, and we have a drug that works on this mechanism. The clinical applications are very direct.”

Related Links:

University of California, San Diego



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

White-Matter Deficits Found in Codeine-Containing Cough Syrup Users

A magnetic resonance imaging (MRI) study of chronic users of codeine-containing cough syrups (CCS) has found deficits in specific regions of brain white matter and linked these changes with increased impulsivity in codeine-containing cough syrup users. These findings were consistent with findings from earlier research of... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.